Literature DB >> 21695417

Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Trevor W Stone1, Caroline M Forrest, Nicholas Stoy, L Gail Darlington.   

Abstract

Several components of the kynurenine pathway of tryptophan metabolism are now recognised to have actions of profound biological importance. These include the ability to modulate the activation of glutamate and nicotinic receptors, to modify the responsiveness of the immune system to inflammation and infection, and to modify the generation and removal of reactive oxygen species. As each of these factors is being recognised increasingly as contributing to major disorders of the central nervous system (CNS), so the potentially fundamental role of the kynurenine pathway in those disorders is presenting a valuable target both for understanding the progress of those disorders and for developing potential drug treatments. This review will summarise some of the evidence for an important contribution of the kynurenines to Huntington's disease and to stroke damage in the CNS. Together with preliminary evidence from a study of kynurenine metabolites after major surgery, an important conclusion is that kynurenine pathway activation closely reflects cognitive function, and may play a significant role in cognitive ability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695417     DOI: 10.1007/s00702-011-0676-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  135 in total

1.  3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.

Authors:  R Schwarcz; E Okuno; R J White; E D Bird; W O Whetsell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

2.  Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.

Authors:  P E Hughes; T Alexi; C E Williams; R G Clark; P D Gluckman
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 3.  Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.

Authors:  S R Thomas; R Stocker
Journal:  Redox Rep       Date:  1999       Impact factor: 4.412

4.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  Activated human microglia produce the excitotoxin quinolinic acid.

Authors:  M G Espey; O N Chernyshev; J F Reinhard; M A Namboodiri; C A Colton
Journal:  Neuroreport       Date:  1997-01-20       Impact factor: 1.837

6.  Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Authors:  P Guidetti; P H Reddy; D A Tagle; R Schwarcz
Journal:  Neurosci Lett       Date:  2000-04-14       Impact factor: 3.046

7.  Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.

Authors:  Flaviano Giorgini; Thomas Möller; Wanda Kwan; Daniel Zwilling; Jennifer L Wacker; Soyon Hong; Li-Chun L Tsai; Christine S Cheah; Robert Schwarcz; Paolo Guidetti; Paul J Muchowski
Journal:  J Biol Chem       Date:  2007-12-13       Impact factor: 5.157

8.  Temporal and spatial changes of quinolinic acid immunoreactivity in the immune system of lipopolysaccharide-stimulated mice.

Authors:  M G Espey; J R Moffett; M A Namboodiri
Journal:  J Leukoc Biol       Date:  1995-02       Impact factor: 4.962

9.  Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.

Authors:  Verónica Pérez-De La Cruz; Diana Elinos-Calderón; Yolanda Robledo-Arratia; Omar N Medina-Campos; José Pedraza-Chaverrí; Syed F Ali; Abel Santamaría
Journal:  Behav Brain Res       Date:  2008-11-30       Impact factor: 3.332

10.  Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.

Authors:  D Jauch; E M Urbańska; P Guidetti; E D Bird; J P Vonsattel; W O Whetsell; R Schwarcz
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

View more
  24 in total

Review 1.  Role of Adiposity-Driven Inflammation in Depressive Morbidity.

Authors:  Lucile Capuron; Julie Lasselin; Nathalie Castanon
Journal:  Neuropsychopharmacology       Date:  2016-07-11       Impact factor: 7.853

2.  Excitotoxic brain injury in adult zebrafish stimulates neurogenesis and long-distance neuronal integration.

Authors:  Kaia Skaggs; Daniel Goldman; Jack M Parent
Journal:  Glia       Date:  2014-07-15       Impact factor: 7.452

3.  Convergent and divergent pathways decoding hierarchical additive mechanisms in treating cerebral ischemia-reperfusion injury.

Authors:  Ying-Ying Zhang; Hai-Xia Li; Yin-Ying Chen; Hong Fang; Ya-Nan Yu; Jun Liu; Zhi-Wei Jing; Zhong Wang; Yong-Yan Wang
Journal:  CNS Neurosci Ther       Date:  2013-12-19       Impact factor: 5.243

4.  Increases in Plasma Tryptophan Are Inversely Associated with Incident Cardiovascular Disease in the Prevención con Dieta Mediterránea (PREDIMED) Study.

Authors:  Edward Yu; Miguel Ruiz-Canela; Marta Guasch-Ferré; Yan Zheng; Estefania Toledo; Clary B Clish; Jordi Salas-Salvadó; Liming Liang; Dong D Wang; Dolores Corella; Montse Fitó; Enrique Gómez-Gracia; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Dora Romaguera; Lluis Serra-Majem; Jose V Sorlí; Frank B Hu; Miguel A Martinez-Gonzalez
Journal:  J Nutr       Date:  2017-02-08       Impact factor: 4.798

5.  Regulation of kynurenine metabolism by a ketogenic diet.

Authors:  Svenja Heischmann; Lindsey B Gano; Kevin Quinn; Li-Ping Liang; Jacek Klepacki; Uwe Christians; Nichole Reisdorph; Manisha Patel
Journal:  J Lipid Res       Date:  2018-03-31       Impact factor: 5.922

Review 6.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  Kynurenines and other novel therapeutic strategies in the treatment of dementia.

Authors:  Zsófia Majláth; János Tajti; László Vécsei
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

8.  Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.

Authors:  Flaviano Giorgini; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Marian A R Thomas; Margarita Tararina; Hui-Qiu Wu; Robert Schwarcz; Paul J Muchowski
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

9.  Prediction of Metabolic Gene Biomarkers for Neurodegenerative Disease by an Integrated Network-Based Approach.

Authors:  Qi Ni; Xianming Su; Jingqi Chen; Weidong Tian
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

10.  RND multidrug efflux pumps: what are they good for?

Authors:  Carolina Alvarez-Ortega; Jorge Olivares; José L Martínez
Journal:  Front Microbiol       Date:  2013-02-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.